HomeHome
TradeTrade
SpotFuturesStocks
LendLendBPBP
ToolsTools
WatchlistsScreenerGraphsCalendarRates
SupportSupport

More

​$​0123456789​.01234567890123456789​

Today

$0.00

+0.00%

Mkt Cap

Volume

Next Earnings

ChartFinancialsEarningsAbout
Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

kyvernatx.com

Ticker

KYTX

Market cap

$332.72M

IPO Date

Feb 8, 2024

Employees

149

All
Crypto
Stocks
Asset

Brokerage services in your region are provided through Trek Brokerage Services Limited, a company licensed by the Anjouan Offshore Finance Authority, acting as Intermediary Broker pursuant to the Backpack Securities Brokerage Services Terms of Service. Please see our Brokerage Services Terms and Conditions available here. Investing in stocks involves risks, including the total loss of your investment. The value of investments can go down as well as up, and past performance is not a reliable indicator of future results. You should consider seeking independent financial or legal advice before making any investment decision. It is your responsibility to ensure that your use of this platform and any investments made comply with the laws and regulations of your jurisdiction.